Response to Brentuximab Vedotin by Cd30 Expression: Results From Five Trials in Ptcl, Ctcl, and B-Cell Lymphomas

Hematological Oncology - United Kingdom
doi 10.1002/hon.149_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

A Phase Ii Trial of Brentuximab Vedotin (Bv) and Lenalidomide (Len) in Relapsed and Refractory (R/R) Cutaneous (Ctcl) and Peripheral (Ptcl) T-Cell Lymphomas: Preliminary Results of a Phase Ii Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Concurrent B-Cell Follicular and Refractory CD30+ Large Cell Transformation of Mycosis Fungoides Responsive to Rituximab and Brentuximab Vedotin

Journal of Blood Disorders & Transfusion
2015English

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Oral Mycosis Fungoides With CD30+ Large Cell Transformation Successfully Treated With Brentuximab Vedotin

JAAD Case Reports
Dermatology
2019English

Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia

OncoTargets and Therapy
OncologyPharmacology
2014English

Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports

Immunopathology, Allergology, Infectology
2018English

Brentuximab Vedotin: New Possibilities for Treatment of Relapses and Refractory Hodgkin’s Lymphomas

Klinicheskaya Onkogematologiya/Clinical Oncohematology
OncologyHematology
2016English

Brentuximab Vedotin for Treatment of Non-Hodgkin Lymphomas: A Systematic Review

Critical Reviews in Oncology/Hematology
GerontologyGeriatricsHematologyOncology
2017English

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy